Modafinil Orion
Wakefulness-Promoting Agent for Narcolepsy
Quick Facts
Key Takeaways
- Modafinil Orion is a prescription-only wakefulness-promoting agent approved for the treatment of narcolepsy in adults.
- The standard adult dose is 200 mg once daily in the morning; doses up to 400 mg may be used under medical supervision.
- It reduces the effectiveness of hormonal contraceptives – alternative contraception is needed during treatment and for two months after stopping.
- Serious skin reactions and psychiatric symptoms (including suicidal thoughts) have been reported – seek immediate medical attention if these occur.
- Not recommended for children under 18, during pregnancy, or for people with uncontrolled hypertension or irregular heartbeat.
What Is Modafinil Orion and What Is It Used For?
Modafinil Orion belongs to a class of medications known as wakefulness-promoting agents, also referred to as eugeroics. Unlike traditional psychostimulants such as amphetamines and methylphenidate, modafinil achieves its wake-promoting effects through a distinct pharmacological mechanism that is associated with a lower risk of jitteriness, rebound hypersomnia, and abuse potential. It was first approved by the United States Food and Drug Administration (FDA) in 1998 and has since become one of the most widely prescribed medications for sleep-wake disorders globally.
Narcolepsy is a chronic neurological condition affecting approximately 25 to 50 per 100,000 people worldwide, according to epidemiological data reviewed by the European Medicines Agency (EMA). The condition is characterised by an inability to regulate the sleep-wake cycle, leading to excessive daytime sleepiness that can severely impair daily functioning, occupational performance, and quality of life. Patients with narcolepsy often experience sudden, irresistible episodes of sleep (sleep attacks) that can occur at any time, including during activities such as driving, working, or eating.
Modafinil is thought to work primarily by inhibiting the reuptake of dopamine through binding to the dopamine transporter (DAT), thereby increasing extracellular dopamine concentrations in wake-promoting brain regions. Research published in the Journal of Clinical Psychiatry and Sleep Medicine Reviews also suggests involvement of noradrenergic, histaminergic, and orexin/hypocretin pathways. This multi-system action promotes sustained wakefulness without the pronounced cardiovascular and peripheral stimulant effects seen with amphetamines.
In clinical trials, modafinil has been shown to significantly improve wakefulness as measured by the Maintenance of Wakefulness Test (MWT) and reduce subjective sleepiness on the Epworth Sleepiness Scale (ESS). A Cochrane systematic review examining drugs for narcolepsy confirmed that modafinil is effective in reducing excessive daytime sleepiness, with a favourable safety profile relative to older stimulants. While modafinil treats the symptoms of narcolepsy, it does not cure the underlying condition. Your doctor may also recommend behavioural strategies such as scheduled naps, sleep hygiene optimisation, and lifestyle modifications alongside medication.
What Should You Know Before Taking Modafinil Orion?
Before initiating treatment with Modafinil Orion, your doctor will conduct a thorough assessment of your medical history, cardiovascular status, and psychological wellbeing. This is important because modafinil has specific contraindications and precautions that must be considered to ensure safe and effective use. The following sections detail the key information you need to be aware of before taking this medication.
Contraindications
You must not take Modafinil Orion if any of the following apply to you:
- Allergy to modafinil or any excipients: If you have previously experienced an allergic reaction to modafinil or any of the inactive ingredients (lactose monohydrate, croscarmellose sodium, povidone K-30, magnesium stearate), you must not take this medicine.
- Irregular heartbeat (arrhythmia): Modafinil can affect cardiac rhythm and is contraindicated in patients with known arrhythmias.
- Uncontrolled moderate-to-severe hypertension: Because modafinil may increase blood pressure, it should not be used in patients whose high blood pressure is not adequately controlled with medication.
Warnings and Precautions
Speak with your doctor or pharmacist before taking Modafinil Orion if you have or have ever had any of the following conditions:
- Heart problems or high blood pressure: Your doctor will need to monitor your cardiovascular health regularly during treatment. Modafinil can increase heart rate and blood pressure, which may be clinically significant in patients with pre-existing cardiovascular disease.
- Mental health conditions: Depression, anxiety, psychosis, mania, or bipolar disorder may be worsened by modafinil. The European Medicines Agency has noted post-marketing reports of psychiatric adverse reactions including suicidal ideation, aggression, and psychotic episodes. If you notice any changes in mood, behaviour, or thoughts of self-harm, contact your doctor immediately.
- Liver or kidney problems: Reduced hepatic or renal function can affect how modafinil is metabolised and excreted. Your doctor may prescribe a lower starting dose (100 mg daily) and monitor you more closely.
- History of substance abuse: Although modafinil has a lower abuse potential than amphetamines, it is classified as a Schedule IV controlled substance in the United States and is subject to prescribing restrictions in many other countries. Patients with a history of alcohol or drug dependence should be monitored carefully.
Long-term use of modafinil may lead to physical or psychological dependence. If you require treatment over an extended period, your doctor will periodically reassess whether modafinil remains the most appropriate medication for your condition. Do not increase your dose or take modafinil more frequently than prescribed.
Children and Adolescents
Modafinil Orion is not approved for use in patients under 18 years of age. Clinical trials in paediatric populations were terminated early due to serious skin reactions, including one case of Stevens-Johnson syndrome. The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefit-risk balance does not support the use of modafinil in children and adolescents.
Pregnancy and Breastfeeding
Modafinil is suspected of causing birth defects (congenital malformations) when used during pregnancy. Data from pregnancy registries and post-marketing surveillance have identified cases of cardiac and orofacial malformations in infants exposed to modafinil in utero. The EMA and FDA both advise against the use of modafinil during pregnancy.
If you are pregnant, think you may be pregnant, or are planning to become pregnant, do not take this medicine. Additionally, because modafinil reduces the effectiveness of hormonal contraceptives, you must use alternative or additional contraceptive methods while taking modafinil and for at least two months after discontinuing treatment. Discuss appropriate contraceptive options with your doctor.
It is not known whether modafinil passes into breast milk. As a precaution, breastfeeding is not recommended during treatment with modafinil.
Driving and Operating Machinery
Modafinil may cause blurred vision or dizziness in some patients. Do not drive or operate machinery if you experience these effects or if you continue to feel excessively sleepy despite taking the medication. You are responsible for assessing your own fitness to drive. Narcolepsy itself poses a significant driving risk, and you should discuss driving fitness with your doctor even when your symptoms are controlled with medication.
How Does Modafinil Orion Interact with Other Drugs?
Modafinil has a clinically significant drug interaction profile due to its effects on hepatic cytochrome P450 (CYP) enzymes. It is a moderate inducer of CYP3A4, meaning it accelerates the metabolism of drugs processed by this enzyme, potentially reducing their effectiveness. It is also an inhibitor of CYP2C19, which can increase blood levels of drugs metabolised by this pathway. Always inform your doctor and pharmacist of all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements.
Major Interactions
| Medication | Effect | Clinical Advice |
|---|---|---|
| Hormonal contraceptives (pills, patches, implants, hormonal IUDs) | Modafinil induces CYP3A4, increasing metabolism of oestrogen and progestogen, reducing contraceptive effectiveness | Use alternative non-hormonal contraception during treatment and for 2 months after stopping |
| Cyclosporine | CYP3A4 induction reduces cyclosporine blood levels, potentially leading to transplant rejection | Monitor cyclosporine levels closely; dose adjustment may be required |
| Warfarin | Modafinil may alter warfarin metabolism, causing unpredictable changes in INR | Frequent INR monitoring required, especially when starting or stopping modafinil |
| Antivirals (ritonavir, indinavir) | Protease inhibitors are CYP3A4 substrates; modafinil may reduce their plasma concentrations | Consult HIV specialist; viral load monitoring recommended |
Other Notable Interactions
| Medication | Effect | Clinical Advice |
|---|---|---|
| Omeprazole | CYP2C19 inhibition may increase omeprazole levels | Monitor for increased omeprazole-related side effects |
| Antiepileptics (carbamazepine, phenytoin, phenobarbital) | These drugs induce CYP3A4 and may reduce modafinil levels; modafinil may also affect their concentrations | Monitor seizure control and drug levels; dose adjustment may be needed |
| Antidepressants (amitriptyline, citalopram, fluoxetine) | CYP2C19 inhibition may increase levels of tricyclics and SSRIs metabolised by this pathway | Monitor for increased antidepressant side effects; dose reduction may be necessary |
| Benzodiazepines (triazolam, midazolam, diazepam) | CYP3A4 induction may reduce benzodiazepine effectiveness; CYP2C19 inhibition may increase diazepam levels | Dose adjustment may be needed; monitor for reduced or increased sedation |
| Statins (atorvastatin, simvastatin) | CYP3A4 induction may reduce statin levels, decreasing cholesterol-lowering effectiveness | Monitor cholesterol levels; lipid panel review recommended |
| Calcium channel blockers (amlodipine, verapamil) | CYP3A4 induction may reduce calcium channel blocker levels | Monitor blood pressure; dose adjustment may be required |
What Is the Correct Dosage of Modafinil Orion?
Always take Modafinil Orion exactly as prescribed by your doctor. The dosage may be individualised based on your clinical response, tolerability, and any coexisting medical conditions. Do not adjust your dose without consulting your prescriber. The following dosage guidelines are based on the approved prescribing information and international clinical guidelines.
Adults (18–64 years)
Standard Dosage
The recommended dose is 200 mg daily. This may be taken as a single 200 mg dose in the morning, or split into two doses: 100 mg in the morning and 100 mg at midday. Taking modafinil later in the day may interfere with nighttime sleep.
In some cases, your doctor may increase the dose to a maximum of 400 mg daily if the initial dose does not provide adequate symptom control. Clinical trials have shown that 400 mg provides minimal additional benefit over 200 mg for most patients, but some individuals may respond better to the higher dose.
Elderly (Over 65 Years)
Reduced Starting Dose
The recommended starting dose for elderly patients is 100 mg daily. This lower initial dose reflects the potential for age-related changes in liver and kidney function that may affect drug metabolism. Your doctor may increase the dose up to a maximum of 400 mg daily if there are no liver or kidney problems and the lower dose is insufficient.
Severe Kidney or Liver Problems
Adjusted Dosage
For patients with severe renal or hepatic impairment, the recommended dose is 100 mg daily. Reduced clearance of modafinil in these populations can lead to increased drug exposure and a higher risk of adverse effects. Your doctor will monitor you regularly and may adjust the dose based on your clinical response and laboratory results.
| Patient Group | Starting Dose | Maximum Dose | Notes |
|---|---|---|---|
| Adults (18–64 years) | 200 mg/day | 400 mg/day | Single morning dose or split AM/midday |
| Elderly (>65 years) | 100 mg/day | 400 mg/day | Without hepatic/renal impairment |
| Severe liver disease | 100 mg/day | 100 mg/day | Regular liver function monitoring |
| Severe kidney disease | 100 mg/day | 100 mg/day | Regular renal function monitoring |
Missed Dose
If you forget to take your dose of Modafinil Orion, take your next dose at the usual time. Do not take a double dose to make up for a missed one, as this may increase the risk of side effects. If you regularly forget doses, consider setting a daily reminder or using a pill organiser to help maintain consistent dosing.
Overdose
What Are the Side Effects of Modafinil Orion?
Like all medicines, Modafinil Orion can cause side effects, although not everyone will experience them. Most side effects are mild to moderate and resolve as your body adjusts to the medication. However, some side effects are serious and require immediate medical attention. The following classification uses internationally standardised frequency categories based on clinical trial data and post-marketing surveillance.
- Difficulty breathing, wheezing, or swelling of the face, mouth, or throat (signs of anaphylaxis)
- Skin rash or itching, especially if it spreads across the body, causes blistering or peeling, or is accompanied by fever or sores in the mouth, eyes, nose, or genitals (signs of Stevens-Johnson syndrome)
- Changes in mental health: mood swings, aggression, hostility, confusion, hallucinations, extreme elation, anxiety, depression, suicidal thoughts or behaviour
Very Common
- Headache
Common
- Dizziness
- Drowsiness or excessive tiredness
- Difficulty sleeping (insomnia)
- Palpitations (feeling your heart beating faster than normal)
- Chest pain
- Flushing
- Dry mouth
- Loss of appetite
- Nausea, stomach pain
- Indigestion
- Diarrhoea or constipation
- Weakness
- Numbness or tingling in hands or feet (paraesthesia)
- Blurred vision
- Abnormal liver function tests (elevated liver enzymes)
- Irritability
Uncommon
- Back pain, neck pain, muscle pain, muscle weakness, leg cramps, joint pain
- Tremor, twitching, or coordination problems
- Vertigo (spinning sensation)
- Difficulty moving muscles smoothly, muscle tension
- Allergic rhinitis symptoms (runny nose, watery eyes)
- Increased cough, asthma, or shortness of breath
- Skin rash, acne, or itching
- Sweating
- Changes in blood pressure (high or low), abnormal ECG, slow heart rate
- Difficulty swallowing, swollen tongue, mouth ulcers
- Excessive gas, acid reflux, increased appetite, weight changes, thirst, taste changes
- Vomiting
- Migraine
- Speech problems
- Elevated blood sugar (diabetes), elevated cholesterol
- Swollen hands and feet
- Sleep disturbance, abnormal dreams
- Decreased libido
- Nosebleeds, sore throat, sinusitis
- Abnormal vision, dry eyes
- Abnormal urination or frequent urination
- Abnormal menstruation
- Changes in white blood cell count
- Restlessness with increased body movement
Reported (Frequency Unknown)
- Swelling under the skin (angioedema) that may be warm or painful
- Raised, red, itchy skin rash (urticaria)
If you experience any side effects not listed here, or if any of the side effects become severe or persistent, contact your doctor or pharmacist. You can also report suspected side effects to your national medicines regulatory authority to help monitor the ongoing safety of this medicine.
How Should You Store Modafinil Orion?
Keep Modafinil Orion out of the sight and reach of children at all times. Store the tablets in their original blister packaging to protect them from moisture and light. There are no special temperature requirements for storage – room temperature is appropriate.
Do not use this medicine after the expiry date stated on the carton, blister pack, and label. The expiry date refers to the last day of the stated month. Do not dispose of medicines via wastewater or household waste. Return unused or expired tablets to your pharmacy for safe disposal. These measures help to protect the environment.
What Does Modafinil Orion Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific substances. The active substance in Modafinil Orion is modafinil. Each tablet contains either 100 mg or 200 mg of modafinil, depending on the strength prescribed.
The inactive ingredients (excipients) are:
- Lactose monohydrate: A sugar-based filler. Each 100 mg tablet contains 107.8 mg of lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
- Croscarmellose sodium: A disintegrant that helps the tablet break apart in the stomach for absorption.
- Povidone (K-30): A binding agent that holds the tablet together.
- Magnesium stearate: A lubricant used in the manufacturing process.
This medicine contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially sodium-free. The 100 mg tablets are white to off-white, capsule-shaped, uncoated tablets imprinted with "41" on one side and "J" on the other side. They are available in PVC/PVdC-aluminium foil blister packs of 30, 90, and 100 tablets. Not all pack sizes may be marketed in your country.
Frequently Asked Questions
Modafinil Orion is used to treat excessive daytime sleepiness caused by narcolepsy in adults. Narcolepsy is a chronic neurological condition that causes overwhelming daytime drowsiness and sudden, uncontrollable sleep episodes. Modafinil promotes wakefulness and helps patients stay alert during the day, reducing the frequency of sleep attacks and improving quality of life.
The recommended dose for adults is 200 mg daily, taken either as a single dose in the morning or split into two doses of 100 mg (morning and midday). For elderly patients or those with severe liver or kidney problems, the starting dose is typically 100 mg daily. Your doctor may increase the dose up to a maximum of 400 mg per day. Always follow your doctor's instructions and do not adjust the dose on your own.
Yes, modafinil can significantly reduce the effectiveness of hormonal contraceptives, including the pill, patch, implant, and hormonal IUD. This is because modafinil increases the activity of liver enzymes (CYP3A4) that break down the hormones in these contraceptives. You must use an alternative or additional non-hormonal method of contraception (such as condoms or a copper IUD) while taking modafinil and for at least two months after stopping treatment.
Modafinil has a lower abuse and dependence potential compared to traditional stimulants like amphetamines. However, some cases of dependence have been reported with long-term use. It is classified as a controlled substance in many countries. Your doctor will regularly review whether continued treatment is appropriate. Never take more than the prescribed dose, and do not share your medication with others.
No. Modafinil is suspected of causing birth defects and should not be taken during pregnancy. If you are pregnant, planning to become pregnant, or breastfeeding, inform your doctor immediately. Because modafinil reduces the effectiveness of hormonal birth control, you must use alternative contraception during treatment and for at least two months after discontinuation.
If you miss a dose, simply take your next dose at the usual time. Do not take a double dose to compensate. Taking modafinil too late in the day can interfere with your sleep at night, so if you remember late in the afternoon or evening, it is best to skip the missed dose entirely and resume your normal schedule the next morning.
References
This article is based on peer-reviewed medical literature and official prescribing information. All medical claims are supported by evidence level 1A (systematic reviews and randomised controlled trials) where available.
- European Medicines Agency (EMA). Modafinil – Summary of Product Characteristics. Updated 2024. Available at: www.ema.europa.eu
- Billiard M, Dauvilliers Y. Narcolepsy. The Lancet. 2024;403(10432):1099–1112.
- Golicki D, Bala MM, Niewada M, Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Medical Science Monitor. 2010;16(8):RA177–186.
- U.S. Food and Drug Administration (FDA). Provigil (modafinil) Prescribing Information. Reference ID: 4908657. Available at: www.fda.gov
- National Institute for Health and Care Excellence (NICE). Narcolepsy: modafinil. Evidence summary. 2023. Available at: www.nice.org.uk
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List (2023). Geneva: WHO; 2023.
- Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477–1502.
- Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry. 2006;67(4):554–566.
- Kallweit U, Bassetti CLA, Goadsby PJ, et al. Narcolepsy: pathophysiology, diagnosis, and treatment. Nature Reviews Neurology. 2023;19(9):519–534.
- British National Formulary (BNF). Modafinil. Updated January 2026. Available at: bnf.nice.org.uk
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specialising in neurology, sleep medicine, and clinical pharmacology. Our editorial process follows the GRADE evidence framework and adheres to international medical guidelines from the WHO, EMA, FDA, NICE, and BNF.
iMedic Medical Editorial Team – Specialists in Neurology and Clinical Pharmacology. All content undergoes dual medical review before publication.
iMedic Medical Review Board – Independent panel ensuring accuracy, completeness, and adherence to current evidence-based guidelines.
All iMedic content is independently produced with no commercial funding or pharmaceutical sponsorship. We follow strict evidence-based methodology and declare no conflicts of interest. For more information, see our Editorial Standards page.